---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-086142"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-06-13T23:59:59+00:00"
generated_at: "2026-05-19T09:53:14.671607+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FibroGen terminates prior HiFiBiO license deal, licenses anti-CCR8 and anti-Gal-9 assets

## Summary
- Terminated Exclusive License and Option Agreement with HiFiBiO dated June 2021, as amended Feb 2024.
- Licensed anti-CCR8 (FG-3175) and anti-Gal-9 (FG-3165) intellectual property to HiFiBiO.
- Eligible for mid single-digit to low double-digit share of HiFiBiO's sublicense revenues and low double-digit share of commercial royalties.
- If HiFiBiO commercializes either asset, FibroGen receives single-digit royalties on worldwide net sales.

## SEC filing metadata
- accession: 0000950170-25-086142
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025086142/0000950170-25-086142-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025086142/fgen-20250612.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-086142
- JSON: https://secwatch.observer/filing/0000950170-25-086142.json
- Plain text: https://secwatch.observer/filing/0000950170-25-086142.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.